News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Fibrocell Science, Inc. Extends Patent Protection for LAVIV® (azficel-T) Through 2031


7/2/2013 8:34:41 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

EXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc. (NYSE MKT:FCSC), creator of the first FDA-approved autologous cellular product, LAVIVĀ® (azficel-T) for aesthetics, announced today that the United States Patent and Trademark Office (USPTO) has awarded a patent to the Company which covers azficel-T fibroblast suspension, extending the patent exclusivity in the United States until 2031.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES